Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Shift From Loss To Profit
This article focuses on Ultragenyx Pharmaceutical Inc.'s financial performance, particularly its recent shift from reporting a loss to anticipated profitability. It highlights analyst expectations and key financial metrics, suggesting a positive outlook for the company's future earnings.
Form 144 ULTRAGENYX PHARMACEUTICAL INC. For: 1 July By Investing.com
This article announces that a Form 144 filling for Ultragenyx Pharmaceutical Inc. was made on July 1st. The brief notice provides the stock symbol RARE, which experienced a -3.02% change, and includes a link to view comments. The content is primarily a filing announcement with associated market data and other Investing.com articles.
RARE (NASDAQ: RARE) affiliate reports insider sales and scheduled awards
An affiliate of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has filed a Form 144, detailing proposed and recent sales of Common Stock and scheduled issuances of Restricted Stock and Performance Shares. The filing indicates open-market sales by Howard Horn totaling over 9,300 shares in May and June 2026, with proceeds exceeding $227,000. It also outlines future stock grants with specific grant dates and share quantities.
RARE - Ultragenyx Pharmaceutical Inc Latest SEC Filings
This article provides a detailed financial overview and snapshot of Ultragenyx Pharmaceutical Inc (RARE), including its market performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It highlights the company's recent stock close, percentage change, and various profitability and efficiency ratios.
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell 1000 Growth Benchmark
Ultragenyx Pharmaceutical Inc. (RARE) has been removed from the Russell 1000 Growth Benchmark. This news comes alongside several other index adjustments for the company, including additions to various Russell 2000 and 3000 benchmarks, and drops from other Russell 1000 and Midcap indices. The biopharmaceutical company focuses on developing products for rare and ultra-rare genetic diseases, with key products like Crysvita and Mepsevii.
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?
Ultragenyx (RARE) shares recently rallied 5.2% due to investor optimism over its growing portfolio of rare disease therapies and a promising late-stage pipeline. Key drivers include products like Crysvita, Dojolvi, and Mepsevii, along with upcoming FDA decisions and clinical trial readouts for other treatments. Despite this, the stock holds a Zacks Rank #3 (Hold), as the consensus EPS estimate for the quarter has remained unchanged, suggesting that further upward movement might depend on future earnings estimate revisions.
Does Ultragenyx (RARE) Shifting Into Small‑Cap Value Indices Recast Its Rare‑Disease Growth Story?
Ultragenyx Pharmaceutical Inc. (RARE) has been reclassified into Russell small-cap and value indices, including the Russell 2000. While this shift impacts its investor base and index-linked demand, the article emphasizes that the core investment narrative remains tied to upcoming FDA decisions for its gene therapies, DTX401 and UX111, in August and September 2026. The company faces ongoing challenges with heavy losses and cash burn despite projections of significant revenue and earnings by 2029.
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?
Ultragenyx (RARE) shares recently rallied 5.2%, closing at $30.77, driven by investor optimism around its growing portfolio of rare disease therapies and a promising late-stage pipeline. The company's flagship products are contributing to revenue growth, and it has several upcoming catalysts, including an FDA decision for DTX401 and readouts for UX701 and GTX-102. Despite expectations of a quarterly loss, analysts are watching earnings estimate revisions for future stock movements, with the stock currently carrying a Zacks Rank #3 (Hold).
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 2000 Value Benchmark
Ultragenyx Pharmaceutical Inc. (NasdaqGS: RARE) has been added to the Russell 2000 Value Benchmark. This news comes after several recent changes in its index inclusions, including being added to the Russell 2000 Growth Benchmark and being dropped from various Russell 1000 and Midcap indices. The company specializes in developing novel products for rare genetic diseases.
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell Small Cap Comp Value Benchmark
Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) has been added to the Russell Small Cap Comp Value Benchmark. The biopharmaceutical company focuses on developing and commercializing treatments for rare genetic diseases, with a pipeline including products like Crysvita, Mepsevii, Dojolvi, and Evkeeza. This inclusion is among several recent updates regarding its placement in various Russell indices.
Enterprise value to EBIT forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE
The article focuses on the enterprise value to EBIT forward metric for Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). It provides a snapshot of the company's financial data as part of a trading platform's market analysis. The content is primarily a data placeholder within a financial information service, with no detailed analysis available in the provided text.
Price to book forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE
This article provides financial information for Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), specifically focusing on its "Price to book forward" metric. The content appears to be a financial data snippet from TradingView, including market information and an overview of the company's financials.
Price to sales forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE
This article provides financial information for Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), specifically focusing on its price to sales forward metric. The content appears to be a financial data page from TradingView, displaying the current market status and available data categories for the company.
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell 1000 Dynamic Index
Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) has been removed from the Russell 1000 Dynamic Index, as announced on June 28, 2026. This news comes alongside similar announcements of its removal from the Russell Midcap Index and Russell 1000 Index on the same day. The company is a biopharmaceutical firm specializing in treatments for rare and ultra-rare genetic diseases, with several products for conditions like XLH, MPS VII, and LC-FAOD.
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) dropped from Russell 1000 Index
Ultragenyx Pharmaceutical Inc. (RARE) has been removed from the Russell 1000 Index. This news follows a recent report of the company's Q1 loss widening and revenue falling, despite reaffirmed earnings guidance for 2026 and initial guidance for 2027. Ultragenyx focuses on developing and commercializing treatments for rare genetic diseases, with products like Crysvita and Mepsevii.
Enterprise value to revenue forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE
This article focuses on the enterprise value to revenue forward metric for Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). It provides financial and stock market information within the TradingView platform context. The content appears to be a stub or a section of a larger financial data presentation rather than an in-depth analysis.
Price to earnings forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE
This article provides financial information for Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), specifically focusing on its Price to Earnings (P/E) forward ratio. It indicates that the market was closed with no trades at the time of publication. The content also lists various data providers contributing to the information presented.
Ultragenyx Pharmaceutical, Inc. Actuals & Estimates (NASDAQ:RARE)
This article provides an overview of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) stock, including its current price, historical performance, and analyst forecasts. It also details financial actuals and estimates for earnings and revenue, noting that the company does not pay dividends and has a market capitalization of $3.03 billion.
Ultragenyx Pharmaceutical, Inc. Actuals & Estimates (BX:UP0)
This article provides actual and estimated financial data for Ultragenyx Pharmaceutical, Inc. (BX:UP0). It covers various financial metrics, analyst forecasts, historical price performance, upcoming earnings dates, and general information about the company's stock, revenue, net income, and market capitalization.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. announced the grant of 44,409 restricted stock units to 15 new non-executive officers. These grants were made under the company's Employment Inducement Plan, effective June 16, 2026, as an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest over four years, with 25% vesting annually from the grant date, provided continuous employment.
Ultragenyx Pharmaceutical Inc. $RARE Shares Bought by Caitong International Asset Management Co. Ltd
Caitong International Asset Management Co. Ltd significantly increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the fourth quarter, now owning 122,854 shares worth approximately $2.83 million. Other major institutions also expanded their holdings, contributing to a high institutional ownership of 97.67%. Despite Ultragenyx missing recent earnings estimates, analysts maintain a "Moderate Buy" consensus rating with an average price target of $59.56.
Ultragenyx Announces Partnership with GeneTx to Advance Treatment for Angelman Syndrome
Ultragenyx Pharmaceutical Inc. has partnered with GeneTx Biotherapeutics LLC to develop GTX-102, an antisense oligonucleotide (ASO), for the treatment of Angelman syndrome. Ultragenyx will make an upfront payment of $20 million for an exclusive option to acquire GeneTx, with the potential for further payments to extend the option period. This partnership aims to advance the first disease-modifying treatment for this serious neurogenetic disorder, with an IND application for GTX-102 expected in the first half of 2020.
Ultragenyx grants 44,409 restricted stock units to 15 new non-executive officers as an inducement.
Ultragenyx Pharmaceutical Inc. has granted 44,409 restricted stock units (RSUs) to 15 newly hired non-executive officers. These RSUs vest over four years, with 25% vesting annually, and are intended to attract and retain talent in the company's efforts to develop therapies for rare diseases. The grant was made under its Employment Inducement Plan and complies with Nasdaq Listing Rule 5635(c)(4).
Ultragenyx awards 44,409 RSUs to 15 new hires
Ultragenyx (NASDAQ: RARE) announced it granted 44,409 restricted stock units (RSUs) to 15 newly hired non-executive officers as an inducement for employment. These awards, approved by the compensation committee and granted on June 16, 2026, will vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to continued employment. This action aligns with Nasdaq Listing Rule 5635(c)(4).
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported the grant of 44,409 restricted stock units to 15 newly hired non-executive officers. These awards were approved by the compensation committee and granted under the Ultragenyx Employment Inducement Plan on June 16, 2026, as an inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest over four years, with 25% vesting annually, conditional on continuous employment.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. reported the grant of 44,409 restricted stock units to 15 newly hired non-executive officers. These awards were made under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2026, and vest over four years. This action is in accordance with Nasdaq Listing Rule 5635(c)(4).
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported granting 44,409 restricted stock units to 15 new non-executive officers. These awards, approved by the compensation committee and granted on June 16, 2026, are an inducement for employment under Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest over four years, with 25% vesting annually, provided continuous employment.
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty
Ultragenyx Pharmaceutical Inc. (RARE) shares dropped 9% after the FDA again denied approval for its UX111 gene therapy for Sanfilippo syndrome type A, leading multiple Wall Street analysts to slash price targets. The company also reported Q4 revenues and a FY26 outlook that missed analyst estimates, alongside a 10% workforce reduction. Despite the setbacks, analysts anticipate future clinical catalysts to shape the company's trajectory towards profitability.
Ultragenyx Pharmaceutical Inc (RARE) Institutional Confidence
Ultragenyx Pharmaceutical Inc (RARE) has achieved a high institutional confidence score of 10.00, ranking first in the Pharmaceuticals industry. Institutional shareholding increased by 3.72% quarter-over-quarter, with prominent investors like Frank Sands, BlackRock, and State Street holding significant shares. This indicates strong institutional interest and investment in the company.
Why (RARE) Price Action Is Critical for Tactical Trading
This article analyzes Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) using AI models, highlighting a strong near and mid-term sentiment contrasting with a weak long-term outlook. It identifies a breakout underway and provides specific tactical trading strategies including long, breakout, and short positions with entry zones, targets, and stop losses. The analysis emphasizes the importance of price action for tactical trading decisions.
Ultragenyx (RARE) Is Up 17.6% After ESOP Share Shelf And Conference Spotlight On Gene Therapies – Has The Bull Case Changed?
Ultragenyx Pharmaceutical Inc. (RARE) recently filed a US$81.53 million share shelf for its employee stock ownership plan and showcased its gene therapy focus at the Goldman Sachs 47th Annual Global Healthcare Conference. These developments, coupled with potential regulatory tailwinds for gene therapy approvals, are influencing investor perception of the company's long-term opportunity and risk profile. The article discusses Ultragenyx's investment narrative, highlighting its gene therapy pipeline, the upcoming UX111 PDUFA decision, ongoing losses, and potential for future dilution.
Ultragenyx (RARE) Is Up 17.6% After ESOP Share Shelf And Conference Spotlight On Gene Therapies – Has The Bull Case Changed?
Ultragenyx Pharmaceutical Inc. shares rose 17.6% after the company filed an US$81.53 million ESOP share shelf and highlighted its gene therapy pipeline at the Goldman Sachs 47th Annual Global Healthcare Conference. These events, combined with potential regulatory tailwinds for gene therapy approvals, are influencing the investment narrative for RARE. Despite the strengthened outlook for gene therapies, investors should remain aware of ongoing losses, a limited cash runway, and potential future equity dilution.
Ultragenyx Pharmaceutical Inc (RARE) Earnings Forecast: Future EPS & Revenue Growth Estimates
Ultragenyx Pharmaceutical Inc (RARE) has an earnings forecast score of 8.40, ranking 37th in the Pharmaceuticals industry. Analysts have set an average price target of $78.50 for RARE, with a consensus "Buy" rating based on 19 analysts. The company's expected revenue for the next quarter is $181.72 million, and the expected EPS is -$1.21.
Ultragenyx (RARE) Is Up 17.6% After ESOP Share Shelf And Conference Spotlight On Gene Therapies – Has The Bull Case Changed?
Ultragenyx (RARE) recently saw its stock rise by 17.6% following the filing of an US$81.53 million ESOP share shelf and its participation in the Goldman Sachs 47th Annual Global Healthcare Conference, where it highlighted its gene therapy pipeline. These developments, along with potential regulatory tailwinds, are influencing investor perception of the company's long-term rare disease opportunity and risk profile. The article discusses how these events impact the investment narrative, emphasizing the importance of future regulatory decisions and the ongoing challenge of managing losses and a limited cash runway.
Ultragenyx EVP sells $46,753 in common stock
Karah Herdman Parschauer, EVP and Chief Legal Officer at Ultragenyx Pharmaceutical Inc., sold 1,899 shares of common stock for $46,753. This transaction, executed under a Rule 10b5-1 trading plan, leaves Ms. Parschauer with 94,462 shares. Despite the sale, InvestingPro analysis suggests the stock is undervalued, and Cantor Fitzgerald recently raised its price target for Ultragenyx.
Ultragenyx director Corazon D. Sanders sells $50,100 in stock
Ultragenyx director Corazon D. Sanders sold 2,000 shares of the company's common stock for $50,100 on June 15, 2026. This transaction leaves Ms. Sanders with 21,095 shares, including Restricted Stock Units subject to vesting. The sale follows recent financial results where Ultragenyx reported a net loss and revenue below analyst expectations, although the company reaffirmed its full-year guidance.
Ultragenyx (RARE) legal chief sells 1,899 company shares in open market
Ultragenyx Pharmaceutical Inc.'s EVP and Chief Legal Officer, Karah Herdman Parschauer, sold 1,899 shares of common stock at $24.62 per share in an open-market transaction. Following this sale, her direct holdings consist of 94,462 shares, which include shares acquired through the company's Employee Stock Purchase Plan and previously reported RSU-based common stock subject to vesting. The transaction is detailed in an SEC Form 4 filing, providing transparency on her equity stake.
Ultragenyx (RARE) director sells 2,000 shares at $25.05
Ultragenyx Pharmaceutical Inc. director Sanders Corazon D. sold 2,000 shares of common stock in an open-market transaction at $25.05 per share. Following this sale, the director directly holds 21,095 shares, which include previously disclosed Restricted Stock Units (RSUs) subject to vesting conditions. The transaction resulted in a net sale of 2,000 shares, valued at $50,100.
RARE (NASDAQ) proposed sale of 2,000 restricted shares by broker-dealer
Morgan Stanley Smith Barney LLC Executive Financial Services has filed a Form 144 notice for the proposed sale of 2,000 restricted shares of Ultragenyx Pharmaceutical Inc. (RARE) on NASDAQ. The shares consist of 1,298 from a 2022 grant and 702 from a 2023 grant. This filing indicates an intent to sell, but does not confirm the actual execution of the sale.
[144] Ultragenyx Pharmaceutical Inc. SEC Filing
This article reports on an SEC Form 144 filing by Ultragenyx Pharmaceutical Inc. (RARE) on June 15, 2026. The filing indicates a proposed sale of 3,799 shares of common stock with an aggregate market value of $92,505.65 through Morgan Stanley Smith Barney LLC. The securities were acquired on March 1, 2025, as Performance Stock Units from the Issuer, and the proposed sale date is June 15, 2026.
Here is Why Ultragenyx Pharmaceutical (RARE) is One of the Best Buy-the-Dip Stocks
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is highlighted as a top buy-the-dip stock, with analysts projecting over 122% upside, and one analyst even setting a target price suggesting nearly 312% upside. The company is expected to benefit from new FDA draft guidance streamlining gene therapy development, especially for genome editing in human somatic cells. Despite a current high cash burn, Ultragenyx focuses on novel therapies for rare genetic diseases and aims for profitability from 2027.
Here is Why Ultragenyx Pharmaceutical (RARE) is One of the Best Buy-the-Dip Stocks
Ultragenyx Pharmaceutical (RARE) is presented as a strong buy-the-dip stock with significant upside potential, based on analyst ratings and its role in gene therapy development. The company is poised to benefit from new FDA draft guidance aimed at streamlining human gene therapies, despite a current high cash burn, with profitability expected from 2027. An analyst from Cantor Fitzgerald recently increased the stock's target price due to the promising statistical success probability of its GTX-102 treatment for Angelman syndrome.
Ultragenyx Pharmaceutical Inc. $RARE Stock Holdings Lifted by GW&K Investment Management LLC
GW&K Investment Management LLC significantly increased its stake in Ultragenyx Pharmaceutical Inc. by 19.6% in the fourth quarter, now owning 1.43% of the company's stock valued at $31.6 million. Despite increased institutional ownership, some insiders, including the CFO and a director, sold shares, and the company reported a wider-than-expected quarterly loss and lower revenue. Analysts, however, maintain an average "Moderate Buy" rating for Ultragenyx, with an average price target of $59.56.
Motley Fool Wealth Management LLC Lowers Position in Ultragenyx Pharmaceutical Inc. $RARE
Motley Fool Wealth Management LLC decreased its stake in Ultragenyx Pharmaceutical Inc. by 16.3% in the fourth quarter of 2025, selling over 58,000 shares. This move comes amidst ongoing insider selling by company executives and a weaker-than-expected earnings report where Ultragenyx missed both revenue and EPS estimates. Despite this, analysts currently rate the stock as a "Moderate Buy" with a consensus price target of $59.56.
Los Angeles Capital Management LLC Sells 60,515 Shares of Ultragenyx Pharmaceutical Inc. $RARE
Los Angeles Capital Management LLC reduced its stake in Ultragenyx Pharmaceutical Inc. by 31% in the fourth quarter, selling 60,515 shares and retaining 134,467 shares valued at $3.09 million. Despite mixed analyst opinions and recent rating cuts, the consensus rating for Ultragenyx remains "Moderate Buy" with an average price target of $59.56. The biopharmaceutical company recently reported a wider-than-expected quarterly loss and lower revenue, missing analyst estimates.
RARE: Transformative year ahead with pivotal data, gene therapy launches, and path to profitability
Ultragenyx Pharmaceutical Inc. (RARE) anticipates a transformative year in 2026, driven by key Phase III Angelman data and the launch of two gene therapies. The company aims for profitability by 2027, supported by strong clinical results, robust manufacturing, and strategic PRV monetization, which also bolsters its financial outlook and pipeline expansion. This outlook is based on insights from the Goldman Sachs 47th Annual Global Healthcare Conference 2026.
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder
Ultragenyx Pharmaceutical Inc. (RARE) received priority review from the FDA for its DTX401 gene therapy, aimed at treating Glycogen Storage Disease Type Ia, a rare metabolic disorder. The FDA is expected to make a decision by August 23rd. This positive development follows recent setbacks for Ultragenyx, including previous rejections for its UX111 gene therapy and disappointing results for Setrusumab (UX143) in osteogenesis imperfecta.
Ultragenyx Pharmaceutical Inc. $RARE Shares Acquired by BNP Paribas Financial Markets
BNP Paribas Financial Markets significantly increased its stake in Ultragenyx Pharmaceutical (NASDAQ:RARE) during the fourth quarter, acquiring an additional 330,031 shares. This move, along with investments from other institutions, highlights strong institutional ownership, with 97.67% of RARE shares held by such entities. Despite this, Ultragenyx reported a quarterly loss and revenue below estimates, and insiders have recently sold shares, contributing to a 6% drop in the stock.
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Upgraded by Wall Street Zen
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its stock rating upgraded by Wall Street Zen from "strong sell" to "sell." Despite the upgrade, the biopharmaceutical company reported a larger-than-expected loss in its latest quarter, missing both earnings and revenue estimates. The stock has been trading below its 50-day and 200-day moving averages, and institutional investors have recently adjusted their holdings.
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm
Kuehn Law is investigating Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) for potential breaches of fiduciary duties by its officers and directors. A federal securities lawsuit alleges the company misrepresented the potential of setrusumab, specifically that while it increases bone density, this does not correlate to reduced fracture rates. Investors who purchased RARE prior to August 3, 2023, are encouraged to contact Kuehn Law.
